See inside every stock. Pro
S&P 5007,624▼ 0.52%Nasdaq25,955▼ 0.21%Dow Jones52,215▼ 1.23%Nasdaq 10028,958▼ 0.00%VIX19.45▲ 2.21%US Dollar101.75▲ 0.14%Gold spot4,012▼ 0.30%WTI103.27▲ 3.82%
← ALNOV page
XStocksXray
Market X-Ray report · 23 October 2026

Novacyt (ALNOV)

Euronext Paris · France · prices in EUR · close of 23 Oct 2026

Key indicators

Last closeEUR 0.464
52-week range0.290 – 1.040
Return, 1 month / 3 months−6.6% / +3.5%
Return, 1 year / 3 years−2.4% / −13.4%
TrendAbove 200-day, below 50-day
RSI (14)45
Volatility (1 year)93.7%
Worst drawdown (1 year)-57.3%
Average daily value traded0.14M EUR
Dividend yield–

Market X-Ray price-based

56/ 100 · High confidence · ahead of 57% of stocks on this exchange
Trend65
Momentum79
Stability (higher is calmer)16
Liquidity66
Income–

Five-year price chart navy: price · brown: 200-day average

0.031.372.704.045.372021-112023-022024-052025-082026-10

About the company

Novacyt is a diagnostics company based in France that develops and supplies molecular testing products. It makes laboratory instruments and reagent kits used to detect infectious diseases and other conditions, serving hospitals, clinical laboratories and healthcare providers. Its work centres on polymerase chain reaction technology and related diagnostic systems, and it also offers testing services through its laboratory operations. The company sells its products to customers in healthcare and research settings across several countries.

Novacyt trades under the code ALNOV on the Euronext Paris in France, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

Novacyt (ALNOV) trades on the Euronext Paris in France. It last closed at EUR 0.464 on 23 October 2026.

Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 270 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price fell 2.4% and over the last three months it rose 3.5%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
Novacyt (ALNOV)

The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris

Lens and metricValueScoreReading
Trend65 · FairMixed trend against its averages.
Above 200-day average4.0%
From 52-week high-48.7%
Momentum79 · StrongRising faster than most stocks on this exchange.
3-month return3.5%
6-month return26.5%
12-month return, skipping the last month4.4%
Stability (higher is calmer)16 · WeakVolatile, with deep drawdowns.
Volatility, 1 year (lower is calmer)93.7%
Worst drawdown, 1 year (smaller is calmer)-57.3%
Liquidity66 · FairModerate trading activity.
Average daily value traded0.14M EUR
Zero-volume days0.0%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

  • Momentum: Rising faster than most stocks on this exchange.

Weak spots

  • Stability (higher is calmer): Volatile, with deep drawdowns.

Returns

1 week−1.4%
1 month−6.6%
3 months+3.5%
6 months+26.5%
1 year−2.4%
3 years−13.4%
5 years−86.4%

Signals

50-day / 200-day average0.493 / 0.446
Golden / death cross (60 days)Golden, 48 days ago
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.021

Technical summary

DailyBearish4 bullish · 2 neutral · 10 bearish
WeeklyNeutral5 bullish · 1 neutral · 6 bearish
MonthlyNeutral4 bullish · 1 neutral · 3 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 24 Oct 2026